URGN: Strong ZUSDURI launch, pipeline innovation, and market expansion drive long-term growth
The company is leveraging proprietary RTGel technology to lead in urothelial cancers, with ZUSDURI's strong launch and first-mover advantage in NMIBC driving growth. Next-generation products and pipeline expansion into high-grade disease and new tumor types support long-term potential.Based on UroG…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.